Description
SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA.
Product information
CAS Number: 2073059-82-0
Molecular Weight: 452.53
Formula: C23H24N4O4S
Chemical Name: N-[4-(4-methoxyphenyl)-1, 3-thiazol-2-yl]-4-{[2-(morpholin-4-yl)-2-oxoethyl]amino}benzamide
Smiles: COC1C=CC(=CC=1)C1=CSC(NC(=O)C2=CC=C(C=C2)NCC(=O)N2CCOCC2)=N1
InChiKey: BMMQYFWEGRLMNT-UHFFFAOYSA-N
InChi: InChI=1S/C23H24N4O4S/c1-30-19-8-4-16(5-9-19)20-15-32-23(25-20)26-22(29)17-2-6-18(7-3-17)24-14-21(28)27-10-12-31-13-11-27/h2-9,15,24H,10-14H2,1H3,(H,25,26,29)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes.
In Vivo:
SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993. SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.